Under the agreement, members of the health plan will have covered access to Biocept's growing menu of circulating tumor cell and circulating tumor DNA tests.
The year in personalized medicine started at the White House and ended with a congressional hearing, capturing the enthusiasm and barriers in the field.
Under a national agreement, UnitedHealthcare will cover the FoundationOne genomic profiling assay in patients with metastatic stage IV non-small cell lung cancer.
The publisher of the Science family of journals will allow some authors to place peer-reviewed versions of their papers into publicly accessible repositories.
